Researchers recently presented their findings on the protective effects of medical therapies recommended to treat heart failure. By pooling together study results, they have confirmed that guideline-recommended heart failure therapies – particularly a combination of RAAS inhibitors plus beta-blockers – protect heart function in patients being treated for cancer.

Researchers have developed a new drug – elraglusib that may help pancreatic cancer patients to live longer. A phase 2 randomized trial showed that the drug along with chemotherapy reduced the risk of death by 38 %.

A new study tested six AI models developed by Meta, Google, Deepseek and Mistral AI and found that AI models can generate more complete summaries of complex cancer pathology reports than physicians.

Compounds from wolfsbane and larkspur have long been linked to pain relief, cancer therapy and other medical applications, but their complexity has hindered production. Researchers have now decoded the first stages of their biosynthesis, opening new possibilities for naturally inspired therapeutics.

A new poll by the Physicians Committee for Responsible Medicine has found out that almost half of the adults in the USA are not aware that eating processed meat increases colon cancer risk. On the other hand, research says that plant-based diet reduces the risk by 22 %.

A new study shows that AI can be used to evaluate the build-up of calcium deposits in the breast arteries from X-ray mammography scans that are used in routine breast cancer screening.

Scientists have discovered a new solution to target cancer causing proteins. They have developed protein like polymers which are capable of grabbing proteins and directing them to the cell’s waste-disposal system.

Decades of basic research on the foodborne pathogen Listeria monocytogenes have culminated in an unexpected medical application: a novel cancer therapy designed to activate the body’s innate immune system.

A study has made a new discovery in cancer signaling and has revealed that it could have important implications for the development of new classes of cancer therapeutics.

Researchers have developed a new laboratory model to study rare tumors—BAP1-deficient melanomas—that are resistant to immunotherapies. The model has the potential to transform how therapies are developed for aggressive melanomas that currently have almost no effective treatment options.